Despite all the reported benefits associated with the use of Anti-TNF therapy, [9–13] it poses an increased risk of infections such as pneumococcal pneumonia, meningococcal meningitis, seasonal influenza, and hepatitis B viral (HBV) infection that can be prevented by vaccination before initiating Anti-TNF therapy [14–17]. Here, TNF is linked to pneumococcal pneumonia.